A previous report identified a PTPRK-RSPO3 fusion gene in CRC and demonstrated that targeting RSPO3 in PTPRK-RSPO3 fusion-positive human tumor xenografts inhibited tumor growth and promoted differentiation (Storm et al. 2016). The gene discussed is PTPRK; the disease is colorectal carcinoma.